about
Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature reviewWhat Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis.Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.NF-κB p65 Subunit Is Modulated by Latent Transforming Growth Factor-β Binding Protein 2 (LTBP2) in Nasopharyngeal Carcinoma HONE1 and HK1 Cells.Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma.Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinomaProposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma.A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma.Nasopharyngeal carcinoma: salvage of local recurrence.Current management of nasopharyngeal cancer.Translational research in nasopharyngeal carcinoma.Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era.Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant.Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective.Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies.A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity.The International Atomic Energy Agency global initiatives on nasopharyngeal cancer treatment.IKBB tumor suppressive role in nasopharyngeal carcinoma via NF-κB-mediated signalling.Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting.Role of MIF/CXCL8/CXCR2 signaling in the growth of nasopharyngeal carcinoma tumor spheres.Parapharyngeal extension of nasopharyngeal carcinoma: still a significant factor in era of modern radiotherapy?Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.MicroRNA profiling study reveals miR-150 in association with metastasis in nasopharyngeal carcinoma.Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials.Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.Should all nasopharyngeal carcinoma with masticator space involvement be staged as T4?Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis.Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma.Is selective neck irradiation safe for node-negative nasopharyngeal carcinoma?Comparison of Planning Quality and Efficiency Between Conventional and Knowledge-based Algorithms in Nasopharyngeal Cancer Patients Using Intensity Modulated Radiation Therapy.International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma.Quality of life in head and neck cancer survivors at 1 year after treatment: the mediating role of unmet supportive care needs.A Mixed-Methods Study of Unmet Supportive Care Needs Among Head and Neck Cancer Survivors.A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma.
P50
Q26771837-00ED9028-A9EE-4573-B0E7-E3CEA51460F7Q31146986-C0D39489-837C-48D8-9BFE-4F40D8DBF364Q33168017-13DB0E7E-A503-45C1-AEA3-E0B2831E8698Q33955955-D4E70D38-0B69-42DF-8DAE-CAD589D8B1F0Q35505126-FCE44FA6-5464-4B73-A312-C6E952EA371CQ35606754-5D9EB845-82EA-4FD8-82F9-CCE9FC7C3781Q35928927-440C2B17-C710-4D5A-A2C3-0762F04475FEQ36742929-E82457EC-80D7-42F3-A4D5-24F6CE00C90DQ37141483-64CFD5F2-8E97-4869-A4FC-770FE85A2CE8Q37323204-6EAB55D6-25FF-4669-897F-937F153E059CQ37327734-61C1DE9A-9C7A-4127-A319-774E334D9996Q37694718-3B7C1FDE-9FD7-436D-BC42-BABB8DC785B8Q37994433-3F23DE13-B8D6-4F68-B8D3-FDB902422315Q38017864-0FF85F82-C415-46AE-BDF0-8F7EC68B3C10Q38170853-FE7D87A3-5909-44CE-AA04-7CCD96F56941Q38196065-E0FA1E1C-2047-4F00-806C-C370DA30533EQ38549748-865FDA5E-BEA9-40C2-ACF2-8CE0BABF0777Q38583301-D4A16971-3502-4E5C-A232-551B04F0E941Q38633649-632DAF1C-122D-4CF8-9B7D-5BF79FB58671Q38702239-10272078-0A10-48FB-8977-0C2CE21C2D36Q38819396-A3DBCB37-6019-4EB5-A588-AC0C7434CFBCQ38847762-CE8B78B7-4430-445A-9C63-3D41A45B7EEAQ38918414-63AD0668-44FB-409E-9C8C-5E6E0A802C47Q38959017-13B6EF1C-03A0-4A86-8248-F469A3A543F2Q39195793-2FCE72D1-9A13-424D-913A-C6FD10A5DEA0Q40102958-314931B6-5EBD-4C2E-8F45-727880B88E31Q41758054-E1AD726B-EB6D-49CB-B52D-DA43712DA1A5Q42278458-E3B279C3-7C25-40AC-A0B6-1EB020A34BD5Q42367839-9CDBE7B5-A243-4F8D-8160-CBA4C80E11B8Q43292345-D22DAFE5-AE3D-4E6E-9E69-477DCA0AD1D0Q43820963-64DC04A1-3978-4A5D-A9A7-4BA5B05B3CDBQ44277439-C128339E-A82B-4CA7-8C9B-A78FD907AC16Q44515604-9DD957F1-0DF4-4107-90E3-6F8AFCDBB8B3Q44740443-AFF25EB8-5C36-4145-A830-2988CC20AAEFQ45953189-01012DC7-DD31-49F2-AB8A-3B41754CC7D8Q46143595-49DD9AF9-B88F-4149-8B1A-F94CDC13B9FCQ46711174-4D607488-2F2F-4E6C-B5F9-F0C387EBEF6AQ47874461-D810DC1E-CFB2-4249-A3E9-F5276622DA14Q47926936-C7616AEA-DB46-46D3-954D-E3909665BEFBQ48509733-D2299C03-8366-49EE-AC57-10458A56E053
P50
description
researcher ORCID ID = 0000-0001-6696-3000
@en
wetenschapper
@nl
name
Wai Tong Ng
@ast
Wai Tong Ng
@en
Wai Tong Ng
@es
Wai Tong Ng
@nl
type
label
Wai Tong Ng
@ast
Wai Tong Ng
@en
Wai Tong Ng
@es
Wai Tong Ng
@nl
prefLabel
Wai Tong Ng
@ast
Wai Tong Ng
@en
Wai Tong Ng
@es
Wai Tong Ng
@nl
P106
P1153
56622104100
P214
4263156223619905400008
P31
P496
0000-0001-6696-3000
P5008
P7859
lccn-n2019184538